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Abstract 
Acute graft-versus-host disease (GVHD) is a life-threatening complication following bone marrow 
transplantation; however, no effective molecular targeting therapy has been determined. Here, we show 
that mice that received allogeneic splenocytes deficient in DNAM-1 had significantly milder GVHD and 
lower mortality than those that received allogeneic wild-type (WT) splenocytes. Donor CD8
+
 T cells 
deficient in DNAM-1 showed significantly less proliferation and infiltration of the liver and intestines of 
recipient mice and produced less interferon (IFN)-γ after coculture with allogeneic splenocytes than WT 
CD8
+
 T cells. Mice prophylactically treated with an anti-DNAM-1 antibody showed milder GVHD and 
lower mortality than those treated with a control antibody. Moreover, treatment with a single 
administration of the antibody after the overt onset of GVHD ameliorated GVHD and prolonged 
survival. Finally, we show that the anti-DNAM-1 antibody therapy also ameliorated the overt GVHD in 
lethally irradiated mice after MHC-matched, minor antigen-mismatched bone marrow transplantation 
(BMT). These results indicate that DNAM-1 plays an important role in the development of GVHD and 
is an ideal molecular target for therapeutic approaches to GVHD. 
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\body 
Introduction 
Allogeneic bone marrow transplantation (BMT) offers therapy for a variety of hematological 
malignancies and for both inherited and acquired non-malignant hematological disorders (1, 2). 
However, the outcome of treatment depends largely on the development of graft-versus-host disease 
(GVHD), a major and mortal complication of allogeneic bone marrow transplantation (3). Alloreactive 
donor T lymphocytes that recognize alloantigens in the host are primed by host antigen-presenting cells 
(APCs), are activated, and mount cellular immune responses against the recipient tissues as “non-self”, 
damaging host tissues, typically in the liver, gastrointestinal tract, and skin (1, 2, 4). However, the 
underlying molecular mechanism is incompletely understood. Although immunosuppressants are widely 
used for prophylaxis and treatment of GVHD, no effective molecular targeting therapy specifically 
targeting the pathogenesis of GVHD has been determined, contributing to poor prognosis of patients 
with higher-grade GVHD (5-7). 
Although the alloantigen-specific signal mediated by the T-cell receptor is essential for priming of 
the pathogenic T cells in GVHD development, a costimulatory signal is required for full activation of 
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the T cells, which leads to the development of exacerbated GVHD (1-3, 8). A strategy to block 
costimulatory signaling has been established: several blocking monoclonal antibodies (mAbs) and 
fusion proteins targeting the interaction between costimulatory molecules expressed on T cells and 
ligands on APCs have been effective in mouse GVHD models (8-12). However, most studies have 
focused on prophylaxis, not on therapy after the onset of GVHD. Although several blocking approaches 
have been used in clinical trials, the effects have been inadequate and even deleterious (5-7, 13-16). 
The leukocyte adhesion molecule DNAX accessory molecule-1 (DNAM-1, also known as CD226) 
is a member of the immunoglobulin (Ig) superfamily and is constitutively expressed on most CD4
+
 T 
cells, CD8
+
 T cells, natural killer (NK) cells, monocytes and macrophages, and platelets (17). The 
poliovirus receptor CD155 and its family member nectin-2 (CD112, also called poliovirus receptor-
related family 2) are ligands for DNAM-1 (18, 19). CD155 and CD112 are broadly distributed on 
hematopoietic, epithelial, and endothelial cells in different amounts in many tissues, as well as in many 
types of tumors, in human and mouse (20-29). Interactions between DNAM-1 on CD8
+
 T cells and NK 
cells and its ligands CD112 and CD155 on target cells augment cell-mediated cytotoxicity (19, 24, 25, 
30). Thus, DNAM-1 is involved in a variety of T-lymphocyte functions for the elicitation of appropriate 
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adaptive immune responses, raising the possibility that it is associated with the severity of several 
diseases, including cancers, autoimmune diseases, and GVHD. 
Here, we explored the role of DNAM-1 in GVHD in a mouse model, and assessed the feasibility of 
novel prophylactic and therapeutic approaches using blocking antibodies against DNAM-1. 
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Results 
DNAM-1 expression on donor CD8
+
 T cells, but not recipient cells, is involved in development of 
acute GVHD 
To examine whether DNAM-1 is involved in the pathogenesis of GVHD, we transplanted splenocytes 
from wild-type (WT) or DNAM-1-deficient (KO) C57BL/6N (B6) (H-2
b
) mice into sublethally 
irradiated B6C3F1 (H-2
b/k
) mice. All the mice that received WT splenocytes died by 50 days after 
transplantation. In contrast, the mice that received DNAM-1 KO splenocytes lived significantly longer 
(Fig. 1A). Histopathological examination showed that mononuclear cell infiltration and hepatocellular 
necrosis in the liver and villous atrophy in the small intestine were clearly milder in recipients of 
DNAM-1-deficient splenocytes (Fig. S1A). Liver dysfunction, as determined by serum alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) values, and the levels of serum interferon 
(IFN)-γ were significantly less elevated in the recipients of DNAM-1-deficient splenocytes (Fig. S1B, C). 
These results indicate that DNAM-1 expressed on donor cells is involved in the development of GVHD. 
 To next examine which cell type of donor cells expressing DNAM-1 plays a critical role in the 
development of GVHD, we prepared both CD4
+
 and CD8
+
 T cells-depleted splenocytes (TCD-SP) from 
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WT B6 mice, and TCD-SP reconstituted with CD4
+
 (derived from DNAM-1 WT or KO mice) and CD8
+
 
T cells (derived from DNAM-1 WT or KO mice). In contrast to B6C3F1 mice that received TCD-SP 
alone, recipient mice transplanted with TCD-SP reconstituted with any combinations of CD4
+
 and CD8
+
 
T cells showed significantly higher levels of ALT and IFN-γ (Fig. S1D, E). Notably, serum levels of 
ALT and IFN-γ were higher in mice that received TCD-SP reconstituted with DNAM-1 WT CD8
+
 T 
cells than those that received DNAM-1 KO CD8
+
 T cells-reconstituted TCD-SP, regardless of DNAM-1 
expression on donor CD4
+
 T cells (Fig. S1D, E). In accordance with these results, recipient mice 
transplanted with TCD-SP reconstituted with both DNAM-1 WT CD8
+
 and WT CD4
+
 T cells showed 
significantly higher mortality than those that received TCD-SP reconstituted with KO CD8
+
 T cells and 
WT CD4
+
 T cells (upper panel in Fig. 1B), while there were no difference in mortality between recipient 
mice transplanted with TCD-SP reconstituted with DNAM-1 WT CD8
+
 T cells and WT CD4
+
 T cells 
and those transplanted with TCD-SP reconstituted with DNAM-1 WT CD8
+
 T cells and KO CD4
+
 T 
cells (lower panel in Fig. 1B). Taken together, these results indicate that DNAM-1 on donor CD8
+
, 
rather than CD4
+
, T cells plays a central role in the development of GVHD. 
 We further examined whether DNAM-1 expressed on recipient cells is also involved in the 
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pathogenesis of GVHD. We established a GVHD model, in which splenocytes from WT B6 mice were 
transplanted into sublethally irradiated WT or DNAM-1 KO CBF1 (H-2
b/d
) mice. A half of mice died by 
20 days after transplantation in both recipient groups and there were no significant difference in survival 
rates between two groups (Fig. 1C), suggesting that DNAM-1 expression on recipient cells is not 
involved in development of acute GVHD. 
 
Anti-DNAM-1 mAb suppresses development of acute GVHD 
To examine whether prophylactic treatment with an anti-DNAM-1 neutralizing mAb, TX42 (Fig. S2A), 
suppressed the development of acute GVHD, we injected WT mice with TX42 or control antibody every 
other day from day -1 until day 17 after transplantation. Although most mice injected with control 
antibody died within 3 months after transplantation, the mice injected with anti-DNAM-1 mAb lived 
significantly longer (Fig. 2A). Moreover, TX42 dramatically ameliorated injury to the liver and small 
intestine, compared with control antibody, on day 25 after splenocyte transfer (Fig. 2B). In accordance 
with the histopathological analysis, TX42 prevented the elevation of serum ALT, AST, and IFN-γ (Fig. 
S3A, B). These results are similar to those in the recipients of the DNAM-1 KO splenocytes, suggesting 
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that blockade of DNAM-1 signaling by using a neutralizing mAb in vivo prophylactically suppressed the 
development of acute GVHD. 
 
Anti-DNAM-1 mAb suppresses donor CD8
+
 T cell proliferation in recipient mice 
To explore the role of DNAM-1 on donor cells in the pathogenesis of GVHD, we first used flow 
cytometry to examine the number of donor CD4
+
 T cells (H-2K
k-
CD4
+
) and CD8
+
 T cells (H-2K
k-
CD8
+
) 
in the peripheral blood during the progression of acute GVHD (Fig. S4A). Although the numbers of 
donor CD4
+
 T cells from DNAM-1 WT and KO mice in the peripheral blood of recipient mice were 
comparable (left panel in Fig. S4B), CD8
+
 T cells derived from DNAM-1 KO mice were present in 
significantly lower numbers than those from DNAM-1 WT mice on day 21 after transplantation (right 
panel in Fig. S4B). Similar results were also observed in mice that received TX42 when compared with 
control antibody (Fig. S4C). Moreover, although the frequencies of total donor-derived hematopoietic 
cells in the liver and small intestine, the major target organs of alloreactive CD8
+
 T cells in GVHD, was 
comparable between two groups that received DNAM-1 WT or KO splenocytes (Fig. S4D), the 
populations of donor CD8
+
 T cells infiltrating into these organs of recipients of DNAM-1 KO 
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splenocytes were significantly smaller than those in recipients of WT splenocytes (Fig. 3A). These 
results indicate that blocking DNAM-1 signaling limits the proliferation of donor CD8
+
 T cells in vivo. 
Most donor CD8
+
 T cells as well as CD4
+ 
T cells from DNAM-1 WT and KO mice differentiated into 
CD44
high
CD62L
low
 effector T cells at day 21 after transplantation (Fig. S5), suggesting that there were 
fewer effector CD8
+
 T cells in proportion to the total CD8
+
 T cells in recipients of DNAM-1 KO vs. WT 
splenocytes or in mice treated with TX42. Taken together with the results shown in Figure 1-3, these 
results suggest that DNAM-1 on donor CD8
+
 T cells plays an important role in cell proliferation and 
infiltration in the liver and small intestine, and is thus involved in the development of acute GVHD. 
 
DNAM-1 costimulation promotes proliferation of and IFN-γ production by alloreactive CD8
+
 T 
cells 
DNAM-1 mediates a costimulatory signal in cytotoxic T cells and promotes cytotoxicity against target 
cells expressing DNAM-1 ligands (30, 31). To examine whether DNAM-1 is also involved in the 
costimulatory effect on proliferation of donor CD8
+
 T cells after priming in vivo, we transplanted CFSE-
labeled splenocytes T cells from B6 mice into sublethally irradiated B6C3F1 or B6 mice. In contrast to 
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CD8
+
 T cells transplanted into syngeneic mice, most DNAM-1 WT CD8
+
 T cells transplanted into 
allogeneic mice had divided at 3 days after transplantation (Fig. S6A), suggesting that the cell division 
resulted from alloantigen recognition. However, fewer DNAM-1 KO CD8
+
 T cells transplanted into 
allogeneic mice divided than did WT CD8
+
 T cells (Fig. S6A), indicating that DNAM-1 mediates a 
costimulatory signal for proliferation in CD8
+
 T cells in vivo. In vivo injection with TX42 mAb on day -
1 and day 1 after transplantation suppressed cell division of donor CD8
+
 T cells (Fig. S6B). To verify 
these results in vitro, we stimulated CFSE-labeled resting CD8
+
 T cells from DNAM-1 WT or KO mice 
with the anti-CD3 mAb plus an anti-DNAM-1 or control Ig. DNAM-1 signaling enhanced the 
proliferation of resting CD8
+
 T cells only when CD8
+
 T cells were simultaneously stimulated with anti-
CD3 mAb (Fig. S6C, D). We also performed the same proliferation assay using donor-derived effector 
CD8
+
 T cells sorted from recipient B6C3F1 mice that had been infused with donor B6 splenocytes. As 
in the resting CD8
+
 T cells, the proliferation of effector CD8
+
 T cells was augmented by DNAM-1 
costimulation (Fig. S6E). The costimulatory effect of DNAM-1 on proliferation was also observed in 
cocultures of resting or effector CD8
+
 T cells with allogeneic stimulators such as whole splenocytes (Fig. 
3B) and either CD11c
+
 or CD11c
-  
cells purified from the spleen (Fig. S6F). Addition of a neutralizing 
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anti-CD155 mAb (TX56) in the assay significantly suppressed the alloantigen-specific CD8
+
 T cell 
proliferation (Fig. S6G), suggesting that CD155 expression on the spelnocytes was involved in DNAM-
1-mediated costimulation in CD8
+
 T cells. Similar to the costimulatory function of DNAM-1 in the 
proliferation of CD8
+
 T cells, DNAM-1 also mediated a costimulatory signal for IFN-γ production by 
resting and effector CD8
+
 T cells (Fig. S6H, I). These results demonstrate that DNAM-1 costimulation 
of alloreactive CD8
+
 T cells promotes the activation and proliferation of and IFN-γ production by 
alloreactive CD8
+
 T cells. 
 
Anti-DNAM-1 mAb suppresses the upregulation of DNAM-1 expression on donor CD4
+
 and CD8
+
 
T cells in recipient mice 
To further investigate the role of DNAM-1 in the pathogenesis of GVHD, we analyzed its expression on 
donor T cells in recipient mice. B6C3F1 recipient mice received CFSE-labeled splenocytes from WT B6 
mice, and the expression of DNAM-1 on donor CD8
+
 T cells was analyzed by flow cytometry 3 days 
after transplantation. The mean fluorescence intensity of DNAM-1 on proliferating donor CD8
+
 T cells 
was significantly higher than that on non-dividing CD8
+
 T cells in recipient mice (Fig. 4A). To examine 
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whether the upregulation of DNAM-1 expression on CD8
+
 T cells was induced by alloantigen 
recognition, B6 or B6C3F1 recipient mice were transplanted with CFSE-labeled splenocytes from WT 
B6 mice. Three days after transplantation, DNAM-1 expression on donor CD8
+
 T cells in the spleen of 
allogeneic recipient mice was significantly higher than that in syngeneic recipients (Fig. 4B). In vitro 
stimulation of CD8
+
 T cells with an anti-CD3 mAb for 3 days also upregulated DNAM-1 expression 
(Fig. 4C). These results suggest that DNAM-1 expression on alloreactive T cells was upregulated during 
proliferation in recipient mice. Of note, DNAM-1 on these donor T cells in recipient mice treated with 
TX42 was significantly less detected by TX42 mAb than in mice treated with control antibody on days 7 
to 21 (Fig. S2C), probably owing to masking of DNAM-1 by injected TX42 in vivo (Fig. S2B). Since 
TX42 mAb is a neutralizing antibody, the masked DNAM-1 on CD8
+
 cells is not functional. Taken 
together, these results suggest that development of acute GVHD is associated with upregulated 
expression of DNAM-1 on donor T cells and anti-DNAM-1 mAb TX42 suppresses DNAM-1 function 
in vivo. 
 
DNAM-1 ligand expression in target organs in acute GVHD 
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We next examined the expression of DNAM-1 ligands Cd112 and Cd155 in target organs in acute 
GVHD. Cd112 was expressed predominantly in the liver, large and small intestines, and kidney (Fig. 
S7). Although Cd155 was expressed at the highest levels in the heart and kidney, the liver and large and 
small intestines also expressed a significant amount of Cd155 (Fig. S7). These results suggest that 
upregulation of DNAM-1 on alloreactive CD8
+
 T cells and constitutively high expression of the ligands, 
particularly CD112, in the liver and intestines are important in the pathogenesis of GVHD. Indeed, the 
levels of functional DNAM-1 expression detected by TX42 mAb on donor CD8
+
 T cells were 
significantly correlated with ALT values (Fig. 4D), suggesting that DNAM-1 expression on CD8
+
 T 
cells plays a critical role in the exacerbation of GVHD. 
 
Therapeutic treatment with a single administration of anti-DNAM-1 mAb ameliorates GVHD 
We next investigated whether treatment with DNAM-1 had a therapeutic effect on overt GVHD. Anti-
DNAM-1 mAb TX42 or control Ig was injected i.p. every week into recipient mice from day 14, when 
GVHD had become overt, to day 77. The mice treated with TX42 mAb showed significantly lower 
mortality, a dramatic improvement of liver dysfunction (as determined by serum ALT and AST values), 
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and decreased IFN-γ in the sera after treatment (Fig. 5A and Fig. S8A, B). Injection of TX42 mAb 
significantly decreased functional DNAM-1 on donor-derived CD8
+ 
T cells, as detected by staining with 
TX42 mAb (Fig. S8C). The amount of functional DNAM-1 on CD8
+ 
T cells was associated with the 
progression of GVHD, because there was a positive and significant correlation between the amount of 
functional DNAM-1 on donor-derived CD8
+
 T cells and ALT values (Fig. S8D). Furthermore, the 
numbers of donor-derived CD8
+
 T cells in the recipients were decreased after treatment with TX42 (Fig. 
S8E). Therefore, the blockade of DNAM-1 signaling by administration of a blocking mAb against 
DNAM-1 in a therapeutic setting could inhibit the expansion of alloreactive effector CD8
+
 T cells even 
after onset of GVHD. To assess the feasibility of the therapeutic approach with anti-DNAM-1 mAb, we 
examined whether a single, rather than multiple, administration of anti-DNAM-1 mAb was also 
effective for the therapy of GVHD.  The mice treated with TX42 mAb only on day 14 also showed 
significantly lower mortality and longer survival (Fig. 5B).  
 
Treatment with anti-DNAM-1 mAb ameliorates GVHD in lethally irradiated mice after MHC-
matched, minor antigen-mismatched BMT 
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Finally, we investigated the involvement of DNAM-1 in the development of GVHD in a more clinical-
relevant GVHD model after minor-mismatched BMT. Bone marrow cells and T cells from B6 mice (H-
2
b
) were transplanted into lethally irradiated minor-mismatched C3.SW-H2
b
-Sn/J (C3) mice (H-2
b
).  
Most recipient mice that were treated with control Ig on day 14 died by 35 days after BMT. In contrast, 
treatment of the recipient mice with a single administration of TX42 mAb on day 14 significantly 
prolonged the survival (Fig. 5C). These results indicate that the administration of a neutralizing mAb 
against DNAM-1 is highly potential for therapy as well as prophylaxis for GVHD in a clinical-relevant 
setting. 
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Discussion 
Given that alloreactive CD8
+
 T cells primed by host APCs presenting alloantigens directly mediate host 
tissue injuries in GVHD (2, 3), it is important that this study has clarified the role of DNAM-1-mediated 
costimulation of pathogenic CD8
+
 T cells in the development of GVHD. Previous works have revealed 
that DNAM-1 plays several important roles in modulating cellular immunity, including: 1) the 
enhancement of cytotoxic T lymphocyte (CTL) (including alloantigen-specific CTL)- and NK cell-
mediated cytotoxicity against target cells expressing CD155 or CD112 and cytokine secretion such as 
IFN-γ, and 2) the proliferation and differentiation of naïve CD4
+
 T cells toward Th1 cells in cooperation 
with leukocyte function-associated antigen-1 (LFA-1) (17, 19, 30, 32). Previous report demonstrated 
that DNAM-1 promoted CD8
+
 T cell proliferation in response to the presentation of superantigens or 
OVA peptide antigens by non-professional APCs but not dendritic cells (31). In contrast, we 
demonstrated that non-professional (CD11c
-
 cells) as well as professional (CD11c
+
) APCs in the spleen 
were involved in the costimulatory effect of DNAM-1 in CD8
+
 T cells.  This discrepancy may be 
explained by the molecular and functional differences between the alloantigens and the OVA peptide 
antigen or superantigens. Although emerging evidence supports the involvement of DNAM-1 in 
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pathogenic T cell-mediated immune diseases, as yet the mechanisms responsible have not been 
identified. Here we have demonstrated that GVHD exacerbation is due to augmentation of the functions 
of pathogenic CD8
+
 T cells by DNAM-1 costimulation, in which the signaling promotes the 
proliferation of alloreactive T cells immediately after priming, as well as the subsequent clonal 
expansion of the T cells in the effector phase in vivo and in vitro. In addition, the enhanced production 
of IFN-γ by CD8
+
 T cells dependent on DNAM-1 costimulation potentially contributes to the 
exacerbation, owing to the immunomodulating effect of IFN-γ on Th1-biased promotion of cellular 
immunity (33). Thus, our results provide definitive evidence of the critical involvement of DNAM-1 in 
the pathogenesis of GVHD and of the immunological mechanisms of the exacerbation of the disease. 
Most conventional molecular targeting strategies using neutralizing mAbs for prophylaxis for 
GVHD focus on blocking the interaction between receptors expressed on pathogenic T cells and the 
ligands on APCs, especially dendritic cells, that leads to priming of T cells in the draining lymph nodes 
in patients with GVHD, e.g., CD28 and CTLA-4-B7, CD40L-CD40, and LFA-1-ICAM (5, 9-12). The 
expression of the ligands for these costimulatory receptors is restricted to professional APCs or 
hematopoietic cells. In contrast, we have shown that two DNAM-1 ligands (CD112 and CD155) are 
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widely distributed not only on hematopoietic cells, but also on nonhematopoietic cells in many tissues in 
mice, including the liver and intestines, the major target organs of GVHD (20-22, 26-29, 34, 35). 
Previous reports demonstrated that the liver expresses Cd155 much more than the other organs in human 
(20, 35). Remarkably, we demonstrated that DNAM-1 expression was upregulated on CD8
+
 T cells after 
priming and was maintained at high levels on effector T cells in recipient mice. Together, these results 
suggest that DNAM-1 is involved in effector phase as well as priming phase of alloreactive CD8
+
 T 
cells that directly attack the target organs expressing DNAM-1 ligands in the host. This may be one of 
the reasons why the treatment with anti-DNAM-1 antibody is effective in the therapy as well as 
prophylaxis for GVHD. 
Patients that received BMT are at the high risk of infectious diseases and relapse of hematological 
and nonhematological tumors under long-term immunosuppressive state. Although the role of DNAM-1 
in immune response against infectious diseases remains to be elucidated, we previously demonstrated 
that DNAM-1 plays an important role in tumor immune surveillance (30). Administration of long-term 
overabundant dose of a neutralizing mAb against DNAM-1 in a clinical application might be deleterious 
due to the impairment of graft-versus-leukemia/ tumor effect (GVL/ GVT effect) in patients; however, 
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attenuation of GVHD with concomitant potent GVL/ GVT effect might be achieved by the regulation of 
dose and timing of administration of a neutralizing mAb against DNAM-1. In fact, we demonstrated that 
only a single dose of anti-DNAM-1 mAb dramatically ameliorated GVHD.  These results encourage us 
to test clinical trials of this antibody therapy for GVHD in patients.  
 The feasibility of conventional strategies for blocking costimulatory molecules in most previous 
work was examined in prophylactic but not therapeutic approaches in mouse GVHD models (9-11, 36, 
37). In sharp contrast, our administration of a neutralizing mAb against DNAM-1 after the clear onset of 
GVHD ameliorated disease by suppressing alloreactive effector CD8
+
 T cell proliferation, IFN-γ 
production and, probably, cytotoxicity against recipient tissue cells. This is the first report using a 
neutralizing mAb against DNAM-1 for the blockade, and it validates the efficacy of this strategy for the 
amelioration of GVHD in both MHC-mismatched transplantation and MHC-matched, minor antigen-
mismatched BMT in mice. Our GVHD model used MHC-mismatched mouse as a donor, which might 
be clinically irrelevant. However, since BMT from one locus of HLA-mismatched donor is frequently 
performed in patients at present, an important point in the present study is that DNAM-1 blocking is able 
to overcome even a high grade GVHD induced by MHC-mismatched transplantation. Nonetheless, 
further works aimed at the association of DNAM-1 and its ligands with GVHD pathogenesis induced by 
transplantation with mismatched minor histocompatibility antigens will be also required for the clinical 
application of DNAM-1-targeting therapy for GVHD. 
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Materials and Methods 
Materials and methods for mice, antibodies, ELISA, assessment of GVHD, infiltrating donor 
lymphocytes, proliferation assays, and quantitative RT-PCR used here are described in SI Materials and 
Methods. 
 
GVHD model. Recipient B6C3F1 mice were sublethally irradiated with 500 cGy by X-ray (Hitachi 
Medical Corporation, Tokyo, Japan). Fifty million splenocytes from DNAM-1 WT or KO B6 mice were 
intravenously infused into each recipient B6C3F1 mouse. For prophylaxis, 100 µg TX42 was injected 
i.p. into the recipient mice 1 day before transplantation (day -1) and then every other day for 9 additional 
doses (total 10 times, 1.0 mg per mouse). For therapy, 300 µg TX42 was injected i.p. beginning on day 
14 and then every week for 9 additional doses (total 10 times, 3.0 mg per mouse), or 1.0 mg TX42 was 
injected i.p. once on day 14. 
 In some experiments, B6C3F1 recipient mice were transplanted with 3.8 x 10
7
 T cell-depleted 
splenocytes (TCD-SP) alone or the same number of TCD-SP plus 7.0 x 10
6
 CD4
+
 T cells (derived from 
DNAM-1 WT or KO mice) and 5.0 x 10
6
 CD8
+
 T cells (derived from DNAM-1 WT or KO mice) after 
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sublethal irradiation with 500 cGy by X-ray. TCD-SP were purified from WT B6 mice by negative 
selection with biotinylated anti-CD4 and CD8 mAbs, followed with Dynabeads MyONE streptavidin 
(Invitrogen, Carlsbad, CA). TCD-SP contained T cells at less than 3%, as determined by flow cytometry. 
CD4
+
 and CD8
+
 T cells were purified from the spleens of DNAM-1 WT or KO B6 mice by negative 
selection with biotinylated anti-B220, CD11b, CD11c, Gr-1, and DX5 (CD49b) mAbs and either 
biotinylated CD8 or CD4 mAbs, followed with Dynabeads MyONE streptavidin. Purities of CD4
+
 and 
CD8
+
 T cells were more than 85%, as determined by flow cytometry.  
 To examine whether DNAM-1 on recipient cells is involved in development of GVHD, we 
generated DNAM-1 WT or KO CBF1 mice (H-2
b/d
) by crossing Cd226
+/-
 Balb/c mice with Cd226
+/-
 B6 
mice. These mice received 1 x 10
7 
splenocytes from WT B6 mice after sublethally irradiation (600 cGy). 
 For a GVHD model after minor-mismatched BMT, recipient C3 mice were lethally irradiated with 
900 cGy one day before BMT (day -1), and then 5 x 10
6
 bone marrow cells and 4 x 10
6
  spleen T cells 
from B6 mice were intravenously infused into each recipient mouse on day 0. 
 
Statistical analyses. To analyze survival we used Kaplan-Meier estimation with the statistical analysis 
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system-type log-rank test. The correlation between DNAM-1 expression levels and ALT values was 
evaluated with Spearman’s rank-order correlation coefficient. All other statistical analyses were 
performed with the two-tailed Mann-Whitney U-test. P < 0.05 was considered statistically significant. 
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Figure Legends 
Fig. 1. DNAM-1 expression on donor CD8
+
 T cells is involved in exacerbation of acute GVHD. 
(A) After sublethal irradiation, B6C3F1 mice received splenocytes from DNAM-1 wild-type (WT) (n = 
14) or knockout (KO) B6 (n = 16) mice. B6C3F1 mice that received irradiation only are also shown (n = 
5). Data are representative of two independent experiments. (B) After sublethal irradiation, B6C3F1 
recipient mice received T cell-depleted splenocytes (TCD-SP) plus CD8
+
 T cells from DNAM-1 WT or 
KO B6 mice and CD4
+
 T cells from DNAM-1 WT or KO B6 mice (n = 10 in each group). Data are 
pooled from two independent experiments. (C) After sublethal irradiation, DNAM-1 WT (n = 9) or KO 
(n = 18) CBF1 mice received splenocytes from DNAM-1 WT B6 mice. DNAM-1 WT and KO CBF1 
mice that received irradiation alone are also shown (n = 5 and 7, respectively). The experiments were 
independently performed four times and pooled data from all the experiments are shown. 
 
Fig. 2. Anti-DNAM-1 mAb suppressed the development of acute GVHD. 
(A) After sublethal irradiation, B6C3F1 mice received splenocytes from WT B6 mice. The recipient 
mice were i.p. injected with anti-DNAM-1 (TX42) (n = 14) or control antibodies (n = 16) every other 
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day from day -1 until day 17 after transplantation. B6C3F1 mice that received irradiation only are also 
shown (n = 10). Data were pooled from three independent experiments. (B) The liver and small intestine 
of mice on day 25 after transplantation were stained with H&E and histologically analyzed. The organs 
of three mice in each group were analyzed and representative data of a mouse in each is shown. Scale 
bars indicate 100 µm. 
  
Fig. 3. DNAM-1 is involved in donor CD8
+
 T cell proliferation in recipient mice after transplantation. 
(A) After sublethal irradiation, B6C3F1 mice received splenocytes from DNAM-1 WT or KO B6 mice. 
The infiltrating cells in the liver and small intestine in recipient mice (n = 3) on day 14 after 
transplantation were separated, and each donor-derived (H-2K
k-
) lymphocyte subset was determined by 
flow cytometry. Data are representative of two independent experiments. (B) Resting CD8
+
 T cells 
purified from naïve DNAM-1 WT or KO B6 mice (left panel) and donor effector CD8
+
 T cells purified 
from B6C3F1 mice that received WT or KO B6 splenocytes (right panel) were labeled with CFSE, 
cocultured with mitomycin C-treated syngeneic (B6) or allogeneic (B6C3F1) splenocytes for 3 days, and 
analyzed by flow cytometry. Data are representative from three independent experiments with similar 
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results. *P < 0.05. Error bars show SD. 
 
Fig. 4. DNAM-1 expression on donor T cells was upregulated in recipient mice. 
(A, B) After sublethal irradiation, B6C3F1 (allogeneic) or B6 (syngeneic) recipient mice received CFSE-
labeled splenocytes from WT B6 mice, and CFSE
+
 donor CD8
+
 T cells in the spleen were analyzed by 
flow cytometry for the expression and mean fluorescence intensity (MFI) of DNAM-1 on day 3 after 
transplantation. (C) CD8
+
 T cells from B6 mice were stimulated with plate-coated anti-CD3 and 
analyzed for the expression of DNAM-1 on CD8
+
 T cells by flow cytometry. (D) The correlation 
between DNAM-1 expression on donor CD8
+
 T cells on day 21 and ALT values on day 28 in recipients 
injected with control Ig or TX42 was statistically evaluated. Data are representative of three independent 
experiments with similar results, respectively. ***P < 0.005, *P < 0.05. Error bars show SD. 
 
Fig. 5. Anti-DNAM-1 mAb ameliorated overt acute GVHD.  
(A, B) B6C3F1 mice received splenocytes from WT B6 mice after sublethal irradiation. The recipient 
mice were injected i.p. with 300 µg anti-DNAM-1 (TX42) (n = 11) or control antibodies (n = 11) every 
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week from day 14 until day 77 after transplantation (A), or 1.0 mg TX42 (n = 19) or control antibodies 
(n = 19) once on day 14 (B). B6C3F1 mice that received irradiation only are also shown (n = 8 or 9). (C) 
C3 mice were transplanted with bone marrow cells and spleen T cells from B6 mice after lethal 
irradiation. The recipient C3 mice were injected i.p. with 1.0 mg TX42 (n = 8) or control antibodies (n = 
8) once on day 14. Recipient B6 mice that received transplantation with bone marrow cells and T cells 
after lethal irradiation (Syngeneic BMT) are also shown (n = 6). Data are representative of two 
independent experiments with similar results in (A). Data are pooled from two independent experiments 
in (B, C). 
 32
Figures 
 
Nabekura et al. 
 
Figure 1 
 
 33
Figure 2 
 
 34
Figure 3 
 
 35
Figure 4 
 
 36
Figure 5 
 
 37
Supporting Information 
 
Nabekura et al. 
 
SI Figures and Figure Legends 
 
 38
 
Fig. S1. DNAM-1 expression on donor CD8
+
 T cells is involved in exacerbation of acute GVHD.  
(A-C) After sublethal irradiation, B6C3F1 mice received splenocytes from DNAM-1 wild-type (WT) (n 
= 14) or knockout (KO) B6 (n = 16) mice. B6C3F1 mice that received irradiation only are also shown (n 
= 5). (A) The liver and small intestine of mice on day 21 after transplantation were stained with 
hematoxylin and eosin (H&E) and histologically analyzed. The organs of three mice in each group were 
analyzed and representative data of a mouse in each is shown. Scale bars indicate 100 µm. (B) ALT and 
AST and (C) IFN-γ in the sera of recipient mice was monitored before and after transplantation. Data are 
representative of two independent experiments. (D, E) After sublethal irradiation, B6C3F1 recipient 
mice received T cell-depleted splenocytes (TCD-SP) plus CD8
+
 T cells from DNAM-1 WT or KO B6 
mice and CD4
+
 T cells from DNAM-1 WT or KO B6 mice (n = 5 in each group). B6C3F1 mice that 
received irradiation alone are shown (n = 3) (D) ALT and (E) IFN-γ in the sera of recipients was 
measured on day 14 after transplantation. The experiments were performed twice, with the similar 
 39
results. One experiment is shown. *P < 0.05, **P < 0.01, ***P < 0.005. Error bars show SD. 
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Fig. S2. Characterization of TX42 mAb in vivo. 
(A) Peripheral blood mononuclear cells (PBMC) from B6C3F1 mice that were i.p. injected with 100 µg 
of control rat IgG2a (upper column) or anti-DNAM-1 mAb, TX42 (rat IgG2a), (lower column) were 
collected 3 days after the injection, and stained with biotin-conjugated TX42 or isotype-matched control 
antibody, followed by FITC-conjugated streptavidin. The PBMC were also stained with FITC-
conjugated anti-rat IgG2a or anti-CD8 mAbs. Cells were analyzed by flow cytometry. Although TX42
+ 
population was not detected by in vitro staining with TX42 in PBMC from the mice on day 3 after TX42 
injection, the DNAM-1
+
 cell
 
population was detected in mice injected with control rat IgG, suggesting 
that the pure TX42 mAb continued to bind to DNAM-1 on cell surface in vivo for more than 3 days. The 
populations of CD8
+
 T cells were comparable between mice that were injected with control IgG and 
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TX42, indicating that TX42 did not deplete CD8
+
 T cells. (B) PBMC from B6C3F1 mice that were 
injected i.p. with 100 µg TX42 were collected at the time indicated after the injection, and stained with 
biotin-conjugated TX42, followed by FITC-conjugated streptavidin. TX42
+ 
population still was not 
detected on day 12 after TX42 injection, but completely recovered on day 20, indicating that TX42 
binding to DNAM-1 on cell surface continues for more than 12 days after TX42 injection. Closed and 
opened histograms show isotype control and the indicated mAb staining, respectively. Data are 
representative of three independent experiments with similar results (A, B). (C) After sublethal 
irradiation, B6C3F1 mice that received DNAM-1 WT splenocytes were i.p. injected with anti-DNAM-1 
(TX42) or control antibody every other day from day -1 until day 17 after transplantation. Mean 
fluorescence intensity (MFI) of DNAM-1 expression on donor CD4
+
 and CD8
+
 T cells in the peripheral 
blood of recipient mice and that on T cells in naïve mice were analyzed by flow cytometry. Data are 
representative of three independent experiments with similar results. *P < 0.05. Error bars show SD. 
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Fig. S3. Anti-DNAM-1 mAb suppressed the development of acute GVHD. 
After sublethal irradiation, B6C3F1 mice received splenocytes from WT B6 mice. The recipient mice 
were i.p. injected with anti-DNAM-1 (TX42) (n = 14) or control antibodies (n = 16) every other day 
from day -1 until day 17 after transplantation. B6C3F1 mice that received irradiation only are also 
shown (n = 10). (A) ALT and AST and (B) IFN-γ in the sera of recipient mice were monitored before 
and after transplantation. Data are pooled from three independent experiments (A, B). *P < 0.05, ***P < 
0.005, control Ig vs. TX42. Error bars show SD. 
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Fig. S4. DNAM-1 is involved in donor CD8
+
 T cell proliferation in recipient mice. 
(A-D) After sublethal irradiation, B6C3F1 mice received splenocytes from WT or KO B6 mice. (C) 
Some of the mice that received WT splenocytes were i.p. injected with anti-DNAM-1 (TX42) or control 
antibodies every other day from day -1 until day 17 after transplantation. (A) Peripheral blood cells from 
the recipient mice were simultaneously stained with FITC-conjugated anti-H-2K
k
, PE-Cy5-conjugated 
anti-CD4, and PE-conjugated anti-CD8 mAbs, and analyzed by flow cytometry. Representative profile 
of flow cytometry data on day 7 after transplantation is shown. Data are representative of more than five 
independent experiments. (B, C) The absolute number of donor CD4
+
 and CD8
+
 T cells in recipient 
peripheral blood was calculated as the number of white blood cells multiplied by the percentage of total 
donor T cells determined by flow cytometric analysis. Data in (B) and (C) are representative of two and 
three independent experiments, respectively. (D) On day 14 and 21 after transplantation, the infiltrating 
donor cells in the liver and small intestine of recipient mice were separated, stained with PerCP-
conjugated anti-CD45.2 and FITC-conjugated anti-H-2K
k
, and analyzed by flow cytometry. Percentages 
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of donor cells (H-2K
k-
 gated by CD45.2
+
) are shown. Experiments were performed twice, with similar 
results. One experiment is shown. *P < 0.05, DNAM-1 WT vs. KO mice (B) or control Ig vs. TX42 (C). 
Error bars show SD. 
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Fig. S5. Differentiation of donor T cells after transplantation. 
After sublethal irradiation, B6C3F1 mice received splenocytes from DNAM-1 WT or KO B6 mice, as 
shown in Fig. 1A. On day 21 after transplantation, PBMC were collected and stained with FITC-
conjugated anti-H-2K
k
, APC-conjugated anti-CD44, PE-conjugated anti-CD62L and either PE-Cy5-
conjugated anti-CD4 or anti-CD8 mAbs and analyzed by flow cytometry. The profiles on H-2K
k-
CD4
+
 
or H-2K
k-
CD8
+
 gates are shown. Experiments were performed twice independently (n = 4 in each 
experiment), with similar results. Data are representative from four mice of one experiment. 
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Fig. S6. DNAM-1 mediates a costimulatory signal in CD8
+
 T cells. 
(A, B) CFSE-labeled splenocytes from DNAM-1 WT (n = 7) or KO (n = 7) B6 mice were transplanted 
into sublethally irradiated B6C3F1 mice (A). Recipient B6C3F1 mice were i.p. injected with anti-
DNAM-1 (TX42) (n = 3) or control antibodies (n = 3) on day -1 and day 1 after transplantation of 
CFSE-labeled splenocytes from WT B6 mice (B). CFSE-labeled splenocytes from B6 mice were infused 
into sublethally irradiated syngeneic mice as a control (n = 3). Proliferation of donor CD8
+
 T cells was 
analyzed by flow cytometry on day 3 after transplantation. (C-E, H) Resting CD8
+
 T cells purified from 
naïve DNAM-1 WT and KO B6 mice (C, D), and donor effector CD8
+
 T cells purified from B6C3F1 
mice that received WT B6 splenocytes (E) were labeled with CFSE, stimulated or not with plate-coated 
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anti-CD3 mAb plus anti-DNAM-1 mAb (TX42) or control antibodies for 3 days, and analyzed by flow 
cytometry (C-E), and by ELISA for IFN-γ level in the culture supernatants (H). Resting CD8
+
 T cells 
purified from naïve DNAM-1 WT or KO B6 mice were labeled with CFSE, cocultured with mitomycin 
C-treated syngeneic (B6) or allogeneic (B6C3F1) splenocytes, dendritic cells (CD11c
+
), CD11-depleted 
splenocytes (CD11c
-
) (F), or a neutralizing mAb against CD155 (TX56)- or control antibody-treated 
splenocytes (G) for 3 days, and analyzed by flow cytometry, and by ELISA for IFN-γ level in the culture 
supernatants (I). Data are representative from two or three independent experiments with similar results 
(A-I). *P < 0.05. Error bars show SD. 
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Fig. S7. Expression of the DNAM-1 ligands. 
Each organ from B6C3F1 mice was subjected to quantitative RT-PCR for Cd155 and Cd112. Data are 
means of triplicates. The experiments were performed independently twice, with similar results. Error 
bars show SD. 
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Fig. S8. Anti-DNAM-1 mAb ameliorated overt acute GVHD. 
B6C3F1 mice received splenocytes from WT B6 mice after sublethal irradiation. The recipient mice 
were injected i.p. with anti-DNAM-1 (TX42) (n = 11) or control antibodies (n = 11) every week from 
day 14 until day 77 after transplantation. B6C3F1 mice that received irradiation only are also shown (n = 
8). (A, B) ALT, AST, and IFN-γ levels in the sera of recipient mice were monitored before and after 
transplantation. (C) MFI of DNAM-1 expression on donor CD8
+
 T cells in the peripheral blood of the 
recipient mice was analyzed by flow cytometry. MFI of DNAM-1 expression on CD8
+
 T cells from 
naïve B6 mice is also shown. (D) The correlation between DNAM-1 expression on donor CD8
+
 T cells 
on day 21 and ALT values on day 28 in recipient mice injected with control Ig or TX42 was statistically 
evaluated. (E) PBMC from the recipient mice were simultaneously stained with FITC-conjugated anti-
H-2K
k
, PE-Cy5-conjugated anti-CD4, and PE-conjugated anti-CD8 mAbs, and analyzed by flow 
cytometry. The absolute number of CD4
+
 and CD8
+
 T cells was calculated, as described in Fig. S4B and 
C. Data are representative of two independent experiments (B-E). *P < 0.05, **P < 0.01, ***P < 0.005, 
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control Ig vs. TX42. Error bars show SD. 
 
